seen from Yemen
seen from Australia
seen from China
seen from United States
seen from Philippines
seen from Honduras
seen from United States
seen from Philippines
seen from United States
seen from United States
seen from United States
seen from Canada
seen from China
seen from China
seen from Canada
seen from United States
seen from Spain
seen from China
seen from Türkiye
seen from China
“Finding” antibodies in a human (after synthetic exosome injection) vs designing antibodies in a lab
Was AbCellera a Robert Malone construct via EpiVax? As part of getting around patent issues? (v2)
207.E : AbCellera antibodies for CV19 likely came from Snohomish County Man blood sample
:
*george Webb…. Not sure what to think.
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Name Transcript
Comply with Q3: 2025-11-06 Earnings Abstract EPS of -$0.19 misses by $0.03 | Income of $8.96M (37.62% Y/Y) beats by $2.62M AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Name November 6, 2025 5:00 PM EST Firm Individuals Tryn Stimart – Chief Authorized Officer, CCO, Compliance Officer, Company Secretary & Privateness OfficerCarl L. Hansen – CEO, President & ChairpersonAndrew Sales space –…
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Name Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Convention Name August 7, 2025 5:00 PM ET Firm Individuals Andrew Sales space – Chief Monetary OfficerCarl L.G. Hansen – CEO, President & ChairpersonTryn T. Stimart – Chief Authorized Officer, CCO, Compliance Officer, Company Secretary & Privateness Officer Convention Name Individuals Brendan Mychal Smith – TD Cowen, Analysis DivisionFaisal…
AbCellera, a Vancouver-based biotechnology company, has recently announced layoffs affecting approximately 20 employees. The company specializes in developing antibody therapies and has been impacted by the ongoing slump in the biotech industry. The layoffs, which represent 10% of AbCellera’s workforce, are a result of the financial challenges faced by the company. The decline in investor […]
Biotech Company AbCellera Faces Layoffs Amidst Industry Slump: What Does This Mean for Antibody Therapies? #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs
AbCellera, a Vancouver-based biotechnology company, has recently announced layoffs affecting approximately 20 employees. The company specializes in developing antibody therapies and has been impacted by the ongoing slump in the biotech industry. The layoffs, which represent 10% of AbCellera’s workforce, are a result of the financial challenges faced by the company. The decline in investor […]
Biotech Company AbCellera Faces Layoffs Amidst Industry Slump: What Does This Mean for Antibody Therapies? #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs
Lilly partner AbCellera adds bispecifics platform to antibody arsenal #AbCellera #bispecifics #EliLilly “Canada’s AbCellera is already a go-to partner for big biopharma antibody discovery efforts, inking deals with the likes of Merck, Pfizer, GlaxoSmithKline and Eli Lilly. Now, it’s adding another tool to its offerings: a bispecifics platform that can combine any two of the antibodies it discovers. AbCellera picked up the platform, dubbed OrthoMab, from Dualogics for an undisclosed amount. And that’s not all—the company also hired Tim Jacobs, Ph.D., who led multiple bispecific antibody programs at Dualogics as its chief technology officer. The acquisition comes after the company raised $105 million in venture capital to boost its antibody work and invest in technologies to complement its discovery engine. Under the deal, AbCellera has full rights to the OrthoMab technology, while Dualogics holds onto the rights to develop its own programs based on the platform, as well as finish out the partnerships it’s already struck.” https://www.instagram.com/p/CEN2ilQDf-j/?igshid=i7j47lxv52n
Bil Gejts: Prva vakcina možda neće biti savršena, a dok se ne pojavi - tu su monoklonska antitela
Bil Gejts: Prva vakcina možda neće biti savršena, a dok se ne pojavi – tu su monoklonska antitela
Gejts je na svom blogu izrazio mišljenje da bi prve vakcine mogle tek da „premoste jaz“ (stop-gap) pre no što one „prave“ postanu dostupne – pre svega bogatim zemljama.
Iako je optimističan u pogledu roka za izlazak prve vakcine protiv korone (početkom sledeće godine), osnivač Microsofta i filantrop koji podržava nekoliko…
View On WordPress
Eli Lilly’s COVID-19 therapy development partner AbCellera raises $105 million – TechCrunch
Eli Lilly’s COVID-19 therapy development partner AbCellera raises $105 million – TechCrunch
When AbCellera won a $30 million contract with the Defense Advanced Research Projects Agency to develop therapeutic countermeasures against viral outbreaks two years ago, it’s safe to assume that no one thought the technology would be so vitally important so soon.
The work AbCellera was doing was part of a high-priority initiative from DARPA’s Biological Technology Office called the Pandemic…
View On WordPress
